EGFR (Domain III) Chimeric Monoclonal Antibody

<strong>EGFR (Domain III) Chimeric Monoclonal Antibody </strong>_x000D_ <strong>Catalog number:</strong> B2017767_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Epidermal Growth Factor Receptor, ErbB-1, HER1_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Greenall SA, McKenzie M, Seminova E, Dolezal O, Pearce L, Bentley J, Kuchibhotla M, Chen SC, McDonald KL, Kornblum HI, Endersby R, Adams TE, Johns TG. Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma Neuro Oncol. 2019 Aug 5;21(8):1016-1027._x000D_ 2: Leung K. 4-[(18)F]Fluorobenzoyl-Phe-Ala-Leu-Gly-Glu-Ala-NH(2) 2011 Aug 26 [updated 2011 Dec 8]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013._x000D_ 3: Luedke E, Jaime-Ramirez AC, Bhave N, Carson WE 3rd. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation J Immunother. 2012 Jun;35(5):367-73._x000D_ 4: Thokala R, Binder ZA, Yin Y, Zhang L, Zhang JV, Zhang DY, Milone MC, Ming GL, Song H, O'Rourke DM. High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms Front Oncol. 2021 Sep 10;11:664236._x000D_ 5: Jiang H, Gao H, Kong J, Song B, Wang P, Shi B, Wang H, Li Z. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell Cancer Immunol Res. 2018 Nov;6(11):1314-1326._x000D_ 6: Chopra A. [(177)Lu]-Labeled α-(5-isothiocyanato-2-methoxyphenyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (MeO-DOTA) conjugated monoclonal antibody L8A4 against epidermal growth factor receptor variant III (EGFRvIII) 2010 Dec 24 [updated 2011 Feb 17]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013._x000D_ 7: Chopra A. [(177)Lu]-Labeled [(R)-2-amino-3-(4-isothiocyanatophenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-pentaacetic acid (CHX-A″-DTPA) conjugated monoclonal antibody L8A4 against epidermal growth factor receptor variant III (EGFRvIII) 2010 Dec 24 [updated 2011 Feb 17]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013._x000D_ 8: Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, He W. Biological drug and drug delivery-mediated immunotherapy Acta Pharm Sin B. 2021 Apr;11(4):941-960._x000D_ 9: Mazzarella L, Guida A, Curigliano G. Cetuximab for treating non-small cell lung cancer Expert Opin Biol Ther. 2018 Apr;18(4):483-493._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/34992090">10: Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram MD. Role of Fcγ receptors in HER2-targeted breast cancer therapy J Immunother Cancer. 2022 Jan;10(1):e003171. </a>_x000D_ _x000D_ <strong>Products Related to EGFR (Domain III) Chimeric Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>